WO2019054808A2 - Utilisation de peptides en tant qu'agent thérapeutique contre des maladies auto-immunes et des maladies osseuses - Google Patents

Utilisation de peptides en tant qu'agent thérapeutique contre des maladies auto-immunes et des maladies osseuses Download PDF

Info

Publication number
WO2019054808A2
WO2019054808A2 PCT/KR2018/010873 KR2018010873W WO2019054808A2 WO 2019054808 A2 WO2019054808 A2 WO 2019054808A2 KR 2018010873 W KR2018010873 W KR 2018010873W WO 2019054808 A2 WO2019054808 A2 WO 2019054808A2
Authority
WO
WIPO (PCT)
Prior art keywords
disease
bone
group
peptide
diseases
Prior art date
Application number
PCT/KR2018/010873
Other languages
English (en)
Korean (ko)
Other versions
WO2019054808A3 (fr
Inventor
조대호
김경은
김면수
박선영
정희영
Original Assignee
주식회사 바이오펩
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP18857312.5A priority Critical patent/EP3682892A4/fr
Priority to AU2018332486A priority patent/AU2018332486B2/en
Priority to JP2020515231A priority patent/JP7122018B2/ja
Priority to CN202311703381.5A priority patent/CN117777239A/zh
Priority to US16/646,069 priority patent/US11629169B2/en
Priority to CA3075607A priority patent/CA3075607A1/fr
Application filed by 주식회사 바이오펩 filed Critical 주식회사 바이오펩
Priority to CN201880059598.8A priority patent/CN111148525B/zh
Priority claimed from KR1020180110480A external-priority patent/KR102166929B1/ko
Priority claimed from KR1020180110473A external-priority patent/KR102166930B1/ko
Publication of WO2019054808A2 publication Critical patent/WO2019054808A2/fr
Publication of WO2019054808A3 publication Critical patent/WO2019054808A3/fr
Priority to US18/174,730 priority patent/US20230234985A1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides

Definitions

  • the present invention relates to the use of a peptide as a therapeutic agent for bone diseases and autoimmune diseases and more specifically to a peptide comprising the amino acid sequence represented by the general formula 1 of the present invention and to a bone disease including osteoporosis of the peptide, Or rheumatoid arthritis, and the like.
  • Bone tissue is composed of various kinds of cells such as extracellular substance such as collagen and glycoprotein, osteoblast, osteoclast, and osteocyte.
  • extracellular substance such as collagen and glycoprotein
  • osteoblast osteoblast
  • osteoclast osteoclast
  • osteocyte a cell that influences the balance between osteoblasts and osteoclasts.
  • bone metabolism and bone remodeling are important for maintaining homeostasis of bone in the balance between osteoblasts that make up the bone matrix and osteoclasts that absorb bone.
  • Bone tissue is composed of various kinds of cells such as extracellular substance such as collagen and glycoprotein, osteoblast, osteoclast, and osteocyte.
  • extracellular substance such as collagen and glycoprotein
  • osteoblast osteoblast
  • osteoclast osteoclast
  • new bone matrix formation and mineralization by osteoblasts are repeated metabolic processes, and bone formation due to osteoblast activity is greater than bone resorption due to osteoclast activity.
  • the bone resurfacing is the process of removing old bone after growth and replacing it with a new bone. It is secreted from bone tissues such as hormone such as parathyroid hormone (PTH), calcitonin, estrogen, etc.
  • PTH parathyroid hormone
  • calcitonin estrogen
  • insulin-like growth factor I It regulates the activity balance of osteoblasts and osteoclasts through cytokines such as various growth factors and tumor necrosis factor-alpha (TNF- ⁇ ), and maintains homeostasis. If the balance between osteoblasts and osteoclasts is broken, it will lead to diseases such as osteoporosis and arthritis.
  • cytokines such as various growth factors and tumor necrosis factor-alpha (TNF- ⁇ )
  • TNF- ⁇ tumor necrosis factor-alpha
  • osteoclasts are specialized cells that are responsible for bone resorption in the bone metabolism process and are formed through differentiation programs from monocytes or macrophages, which are progenitor cells.
  • monocytes or macrophages which are progenitor cells.
  • osteoclasts bind to bone through ⁇ v ⁇ 3 integrin or the like to form an acidic environment and secrete various collagenases and proteases to cause bone resorption, Suppression of cells can be an effective method of treating bone disease.
  • autoimmune diseases are caused by the immune system of the human body, which causes self-cells to attack their own cells.
  • the human immune system basically recognizes microorganisms invading the human body and cancer cell development as external antigens, and has strong power to attack and remove them, but it does not attack against the self cells because of its self-tolerance. This is called the self-tolerance phenomenon of the human body.
  • self-tolerance of the immune system is destroyed, the body reacts to its own cell (or autoantigen), activates autoreactive T cells, and autoantibodies are constantly destroyed, causing inflammation and an immune response .
  • T cells and B cells are specific for the antigen in the immune system.
  • T cells respond to specific antigens presented by antigen presenting cells.
  • the antigen presented in the antigen-presenting cells is recognized as 'non-self', the immune system Response, and when it is recognized as 'self', the immune response is neglected.
  • T cells are activated against an antigen, most of the B cells are activated one after another, and B cells turn into plasma cells, producing antibodies that specifically react to the recognized specific antigen. Therefore, when autoimmunity occurs, the T cell abnormally recognizes the autoantigen and activates the B cell, thus generating an autoantibody that reacts with the autoantigen. An immune response occurs.
  • organ transplantation after organ transplantation recognizes the tissue as 'non-self', resulting in rejection of organ transplantation that attempts to attack and remove the transplanted organ.
  • various immunosuppressants have been used, such as inhibiting the activation of immune cells and inhibiting migration of immune cells to transplanted organs.
  • continuous immunosuppressants causes various side effects.
  • Th17 cells a CD4 + T cell line
  • IL-17 secreted from these cells is directly associated with autoimmune diseases But it is getting bigger as it is revealed that there is a relationship.
  • Th17 cells induce RANKL and several inflammatory cytokines (Chabaud and Miossec, 2001; Connell and McInnes, 2006), which are known to further activate the inflammatory and joint destruction mechanisms. Therefore, since Th17 cells are recognized as a key tumor cell in the signal transduction process related to autoimmune diseases including osteoarthritis and bone diseases, candidate substances that effectively inhibit Th17 cell differentiation are required to be discovered.
  • rheumatoid arthritis is an inflammatory disease characterized by polyarthritis, an autoimmune phenomenon is known as a major mechanism. Symptoms include inflammation of synovial membrane tissue, macrophages, dendritic cells, T lymphocytes, and B lymphocytes, which migrate to synovial tissue, resulting in increased joint fluid and joint pain. When inflammation continues, hyperplasia of inflammatory synovial tissue destroys bones and cartilage, deforming the joint structure and causing movement disorder.
  • inflammatory cytokines in rheumatoid arthritis patients produce collagenase and protease in synovial fibroblasts and chondrocytes and these enzymes destroy collagen and proteoglycan And it is known to destroy cartilage.
  • the present inventors have made efforts to develop a new therapeutic agent for bone diseases and autoimmune diseases having an effective therapeutic effect while minimizing adverse effects as therapeutic agents.
  • the present inventors have found that the peptide produced by the present invention is useful as a bone or osteoporosis-
  • the present invention has been completed based on the finding that the compounds of the present invention can be effectively used for the treatment of autoimmune diseases including arthritis.
  • X 1 to X 3 are each independently selected from the group consisting of proline P, serine S, threonine T, glutamine Q, asparagine N, and cysteine C ), ≪ / RTI >
  • the peptides of the present invention significantly inhibited T cell (T cell) activity and Th17 cell (T helper 17 cell) differentiation associated with autoimmune diseases, and it was confirmed that the peptides have a remarkable effect of treating and improving arthritis in an animal model of arthritis .
  • the peptides may be used as active ingredients in various autoimmune disease therapeutic agents such as bone diseases, inflammatory diseases or rheumatoid arthritis.
  • 1 is a graph showing the population (%) of active T cells by the synthetic peptides of the present invention.
  • Figure 2 is a graph showing the population (%) of active T cells by the synthetic peptide of the present invention.
  • Fig. 3 is a graph showing percent inhibition of T cell activation by the synthetic peptide of the present invention.
  • FIG. 4 is a graph showing the inhibitory effect of Th17 cell differentiation on the synthetic peptide of the present invention.
  • FIG. 5 is a schematic diagram schematically showing the preparation process of the collagen-induced arthritis mouse model and the administration time of the peptide according to the present invention.
  • FIG. 6 is a graph showing the effect of the Pep1 peptide of the present invention on improving arthritis.
  • FIG. 7 is a graph showing the arthritis improving effect of the Pep2 peptide of the present invention.
  • FIG. 8 is a graph showing the arthritis improving effect of the Pep4 peptide of the present invention.
  • FIG. 9 is a graph showing the arthritis improving effect of the Pep6 peptide of the present invention.
  • Peptide " of the present invention means a polymer composed of two or more amino acids linked by an amide bond (or a peptide bond).
  • Stability " of the present invention also means storage stability (e.g., room temperature storage stability) as well as in vivo stability that protects the peptide of the present invention from attack by a protein cleaving enzyme in vivo.
  • prophylactic of the present invention is meant any action which inhibits the disease or delays its development by administration of the pharmaceutical composition according to the invention.
  • treatment means any action that improves or alters the symptoms of the disease by administration of the pharmaceutical composition according to the present invention.
  • individual of the present invention means a subject in need of treatment of a disease, and more specifically refers to mammals such as primates, mice, dogs, cats, horses and cattle, which are human or non-human.
  • &Quot; Improvement of the present invention means all actions that at least reduce the degree of symptom associated with the condition being treated, for example.
  • the present invention is a.
  • peptide comprising the amino acid sequence of the general formula 1 described in the following SEQ ID NO: 1, and a pharmaceutical composition for preventing and treating bone diseases, inflammatory diseases or autoimmune diseases containing the peptide as an active ingredient:
  • X 1 to X 3 are preferably any one selected from the group consisting of proline (P), serine (S) and threonine (T), and proline Serine (S) is more preferable, but is not limited thereto.
  • n is preferably an integer of 1 to 6, more preferably 1 to 3.
  • the peptides of the present invention can be obtained by a variety of methods well known in the art. As an example, it can be produced by polynucleotide recombination and protein expression system, by synthesis in vitro through chemical synthesis such as peptide synthesis, and by cell-free protein synthesis.
  • a protecting group may be attached at the terminal.
  • the protecting group may be an acetyl group, a fluorenylmethoxycarbonyl group, a formyl group, a palmitoyl group, a myristyl group, a stearyl group or a polyethylene glycol (PEG), but it is preferable to modify the peptide,
  • the ingredients may be included without limitation.
  • the above bone diseases include osteoarthritis, osteoporosis, bone metastatic cancer, solid tumor bone metastasis, musculoskeletal complications due to solid tumor metastasis, hypercalcemia due to malignant tumors, multiple myeloma, primary bone tumor, periodontal disease, Inflammatory alveolar bone disorder, inflammatory alveolar bone disorder, inflammatory bone resorption disease, Paget's disease, and the like, but is not limited thereto.
  • the inflammatory disease is selected from the group consisting of atopic, psoriasis, dermatitis, allergies, arthritis, rhinitis, otitis, sore throat, tonsillitis, cystitis, nephritis, pelvic inflammatory disease, Crohn's disease, ulcerative colitis, ankylosing spondylitis, systemic lupus erythematodes (Including but not limited to asthma, edema, delayed allergy (type IV allergy), graft rejection, graft versus host disease, autoimmune encephalomyelitis, multiple sclerosis, inflammatory bowel disease, cystic fibrosis, diabetic retinopathy, ischemia- Nephritis, and gastrointestinal allergy.
  • the present invention is not limited thereto.
  • the autoimmune disease may be selected from the group consisting of rheumatoid arthritis, Sjogren's syndrome, systemic sclerosis, polymyositis, systemic angitis, mixed connective tissue disease, Crohn's disease, Hashimoto's disease, Grave's disease, Goodpasture's sydrome, Guillain-Barre syndrome, idiopathic thrombocytopenic purpura, irritable bowel syndrome, But are not limited to, those selected from the group consisting of myasthenia gravis, narcolepsy, imaginative pemphigus, malignant anemia, primary biliary cirrhosis, ulcerative colitis, vasculitis, Wegener's granulomatosis and psoriasis.
  • polynucleotides encoding the peptides of the present invention are also included in the present invention, since the same therapeutic effects can be obtained by using the polynucleotides encoding the peptides of the present invention.
  • the present inventors prepared various peptides using the above general formula 1 [(X 1 -X 2 -X 3 ) n ] (see Table 1).
  • the present inventors found that the peptides of Table 1 significantly inhibited T cell activity by an average of 15 to 25%, and inhibited the T cell activity of arbitrarily selected peptides The effect is shown in Figs. 1 to 3 (see Fig. 3 also in Fig. 1).
  • the present inventors confirmed that the synthetic peptides prepared in Example 1 were effective in inhibiting Th17 cell differentiation, and as a result, it was confirmed that the peptides of the present invention significantly inhibited Th17 cell differentiation (see FIG. 4) .
  • the present inventors confirmed the therapeutic effects of the peptides of the present invention after producing an animal model of rheumatoid arthritis (see FIG. 5). As a result, they showed significant arthritis-improving effects and particularly similar effects to the positive control MTX (See Figs. 6 to 9).
  • the peptides of the present invention significantly inhibit T cell (T cell) activity and Th17 cell (T helper 17 cell) differentiation associated with autoimmune diseases, and have remarkable arthritis treatment and improvement effect in an arthritic animal model
  • the peptides can be effectively used as an active ingredient in various autoimmune disease therapeutic agents such as bone diseases, inflammatory diseases or rheumatoid arthritis.
  • the peptides of the invention or polynucleotides encoding them can be delivered to a pharmaceutically acceptable carrier such as a colloidal suspension, powder, saline, lipid, liposome, microspheres, or nanospheric particles. They may be associated with or associated with carriers and may be in the form of lipids, liposomes, microparticles, gold, nanoparticles, polymers, condensation reagents, polysaccharides, polyamino acids, dendrimers, saponins, And can be delivered in vivo using known delivery systems.
  • a pharmaceutically acceptable carrier such as a colloidal suspension, powder, saline, lipid, liposome, microspheres, or nanospheric particles. They may be associated with or associated with carriers and may be in the form of lipids, liposomes, microparticles, gold, nanoparticles, polymers, condensation reagents, polysaccharides, polyamino acids, dendrimers, saponins
  • pharmaceutically acceptable carriers may be formulated with pharmaceutically acceptable carriers such as lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia, rubber, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, But are not limited to, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. Further, in addition to the above components, a lubricant, a wetting agent, a sweetener, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, and the like may be further included.
  • pharmaceutically acceptable carriers such as lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia, rubber, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, But are
  • the pharmaceutical composition of the present invention may be administered orally or parenterally (for example, intramuscularly, intravenously, intraperitoneally, subcutaneously, intradermally, or topically) depending on the intended method,
  • parenterally for example, intramuscularly, intravenously, intraperitoneally, subcutaneously, intradermally, or topically
  • the severity and severity of the disease, the form of the drug, the route of administration and the time of administration may be appropriately selected by those skilled in the art.
  • the pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount.
  • pharmaceutically effective amount means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level will depend on the type of disease, severity, The sensitivity to the drug, the time of administration, the route of administration and the rate of release, the duration of the treatment, factors including co-administered drugs, and other factors well known in the medical arts.
  • the pharmaceutical composition according to the present invention can be administered as an individual therapeutic agent or in combination with other bone diseases, inflammatory diseases, or autoimmune disease therapeutic agents, and can be administered separately, simultaneously with a conventional bone disease, inflammatory disease or autoimmune disease therapeutic agent , Or sequentially, and may be administered singly or multiply. It is important to take into account all of the above factors and to administer the amount in which the maximum effect can be obtained in a minimal amount without side effects, which can be easily determined by those skilled in the art.
  • the effective amount of the pharmaceutical composition of the present invention may vary depending on the patient's age, sex, condition, body weight, absorbency of the active ingredient, inactivity, excretion rate, disease type, The severity of obesity, sex, weight, age, and the like.
  • the present invention also provides a health food for preventing or ameliorating bone diseases, inflammatory diseases or autoimmune diseases comprising the peptide of the present invention or a polynucleotide encoding the same as an active ingredient.
  • the health food may be used either simultaneously with or separately from the medicament for treatment before or after the onset of the disease for the prevention or improvement of the disease.
  • the active ingredient may be directly added to the food or may be used together with other food or food ingredients, and suitably used according to a conventional method.
  • the amount of the active ingredient to be mixed can be suitably determined according to the intended use (for prevention or improvement).
  • the composition of the present invention may be added in an amount of preferably not more than 15% by weight, preferably not more than 10% by weight, based on the raw material.
  • the amount may be less than the above range.
  • the health food of the present invention may contain other ingredients as an essential ingredient without any particular limitations other than those containing the active ingredient.
  • various flavoring agents or natural carbohydrates may be added as an additional ingredient, such as ordinary beverages.
  • natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And polysaccharides, for example, conventional sugars such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol.
  • the health food of the present invention may further contain various additives such as various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and heavies (cheese, chocolate etc.), pectic acid and its salts, Salts thereof, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks, and the like.
  • additives such as various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and heavies (cheese, chocolate etc.), pectic acid and its salts, Salts thereof, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks, and the like.
  • additives such as various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and heavie
  • X 1 to X 3 are each independently selected from the group consisting of proline P, serine S, threonine T, glutamine Q, asparagine N, and cysteine C ), ≪ / RTI >
  • CD3 antibody was coated on a 96-well plate and incubated overnight at 4 ° C to prepare 96 wells with CD3 antibody. Then, the naive T cells extracted from the mouse were seeded at a density of 1 ⁇ 10 5 / well on a 96-well plate, treated with each of the synthetic peptides prepared in Example 1 for 18 hours, and then subjected to flow cytometry to obtain active T The population of cells was confirmed. For this purpose, the same number of cells were collected from each cultured group and washed with PBS. Rabbit anti-mouse CD4, which is a helper T cell marker, and rabbit anti-mouse CD69 antibody, which is an activation marker of T cells, staining procedure. After washing with PBS, CD4 + CD69 + T cell population was analyzed.
  • Example 1 As a result, it was confirmed that the peptides synthesized in Example 1 significantly inhibited T cell activity by an average of 15 to 25%.
  • the activation T cells were increased to 74.8% in the CD3 antibody-activated group and decreased to 55 to 62% in the group treated with each synthetic peptide compared with the group without activation (0.98%) .
  • the inhibitory rate of active T cells of each synthetic peptide was about 15% to 25% as in the case of the peptide synthesized in Example 1.
  • the synthetic peptide of the present invention can be effectively used for the treatment of autoimmune diseases by significantly inhibiting T cell activity (FIGS. 1 to 3).
  • naive CD4 + T cells extracted from mouse lymph nodes were incubated with 20 ng / ml of IL-6 and TGF-beta 5 ng / ml to induce differentiation into Th17 cells.
  • the group which induced Th17 differentiation showed a tendency to increase about 2.5 times (3.14%) in the group inducing Th17 differentiation compared to the group that did not induce differentiation into Th17 cells (1.2% In the groups treated with Pep4 peptides, it was confirmed that the proportion of Th17 cells was decreased similarly to the group not inducing differentiation (Fig. 4).
  • a rheumatoid arthritis mouse model was prepared by referring to the known literature (Nat Protoc. 2007; 2 (5): 1269-75) in order to confirm the effect of the peptide prepared in Example 1 for improving rheumatoid arthritis.
  • the CIA mouse model is an autoimmune disease arthritis model similar to human rheumatoid arthritis, and is the most commonly used mouse model in rheumatoid arthritis animal experiments.
  • CIA mice were first emulsified by mixing 1: 1 of bovine type II collagen (Bovine type II collagen, Chondrex, USA) and Freund's complete adjuvant (Chondrex, USA) 50 ⁇ l of collagen solution was injected intradermally into the tail of DBA / 1J mouse at 6 weeks of age to perform primary immunization. After the first immunization, bovine type 2 collagen and Freund's incomplete adjuvant (Chondrex, USA) were mixed at a ratio of 1: 1 and emulsified.
  • bovine type II collagen Bovine type II collagen, Chondrex, USA
  • Freund's complete adjuvant Chondrex, USA
  • each peptide was administered intraperitoneally three times a week from the next day, and the effect of the peptide on the treatment of rheumatoid arthritis was observed.
  • the administered peptides were selected as the four peptides (Pep1, Pep2, Pep4, Pep6) shown in Table 2 (Fig. 5).
  • the degree of progression of rheumatoid arthritis with time was evaluated by evaluating the rheumatoid arthritis progression index.
  • the arthritic progression index was expressed as 0 to 16 points (total of four legs) in total by evaluating the arthritic progression index from 0 to 4 points for each leg according to Rossolinec et al.
  • the severity of arthritis was quantified by calculating the average value of the results evaluated by the observer.
  • FIGS. 6 to 9 it can be seen that the arthritic score is significantly increased in the CIA-induced mouse (Vehicle control) compared with the normal mouse group, Pep1, Pep2, Pep4, and Pep6) were intraperitoneally administered, respectively. In addition, it was confirmed that similar efficacy was shown to the positive control MTX (Figs. 6 to 9).
  • the peptide of the present invention can be used as a therapeutic agent for various bone diseases and autoimmune diseases including arthritis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne l'utilisation de peptides en tant qu'agent thérapeutique. Il a été confirmé que les peptides selon la présente invention inhibent significativement l'activité des lymphocytes T et la différenciation des lymphocytes T auxiliaires 17 (lymphocytes Th17), qui sont associés à des maladies auto-immunes, et présentent des effets remarquables en matière de traitement et d'amélioration de l'arthrite chez un modèle animal de l'arthrite. Par conséquent, les peptides peuvent être utilisés en tant que principe actif dans des agents thérapeutiques contre diverses maladies auto-immunes telles que des maladies osseuses, des maladies inflammatoires ou la polyarthrite rhumatoïde.
PCT/KR2018/010873 2017-09-15 2018-09-14 Utilisation de peptides en tant qu'agent thérapeutique contre des maladies auto-immunes et des maladies osseuses WO2019054808A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU2018332486A AU2018332486B2 (en) 2017-09-15 2018-09-14 Use of peptides as therapeutic agent for autoimmune diseases and bone diseases
JP2020515231A JP7122018B2 (ja) 2017-09-15 2018-09-14 自己免疫疾患および骨疾患の治療剤としてのペプチドの用途
CN202311703381.5A CN117777239A (zh) 2017-09-15 2018-09-14 作为自身免疫疾病及骨病治疗剂的肽的用途
US16/646,069 US11629169B2 (en) 2017-09-15 2018-09-14 Use of peptides as therapeutic agent for autoimmune diseases and bone diseases
CA3075607A CA3075607A1 (fr) 2017-09-15 2018-09-14 Utilisation de peptides en tant qu'agent therapeutique contre des maladies auto-immunes et des maladies osseuses
EP18857312.5A EP3682892A4 (fr) 2017-09-15 2018-09-14 Utilisation de peptides en tant qu'agent thérapeutique contre des maladies auto-immunes et des maladies osseuses
CN201880059598.8A CN111148525B (zh) 2017-09-15 2018-09-14 作为自身免疫疾病及骨病治疗剂的肽的用途
US18/174,730 US20230234985A1 (en) 2017-09-15 2023-02-27 Use of peptides as therapeutic agent for autoimmune diseases and bone diseases

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
KR20170118947 2017-09-15
KR10-2017-0118947 2017-09-15
KR10-2017-0118949 2017-09-15
KR20170118949 2017-09-15
KR10-2018-0110473 2018-09-14
KR1020180110480A KR102166929B1 (ko) 2017-09-15 2018-09-14 자가면역질환 치료제로서의 펩타이드의 용도
KR1020180110473A KR102166930B1 (ko) 2017-09-15 2018-09-14 골질환 치료제로서의 펩타이드의 용도
KR10-2018-0110480 2018-09-14

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/646,069 A-371-Of-International US11629169B2 (en) 2017-09-15 2018-09-14 Use of peptides as therapeutic agent for autoimmune diseases and bone diseases
US18/174,730 Continuation US20230234985A1 (en) 2017-09-15 2023-02-27 Use of peptides as therapeutic agent for autoimmune diseases and bone diseases

Publications (2)

Publication Number Publication Date
WO2019054808A2 true WO2019054808A2 (fr) 2019-03-21
WO2019054808A3 WO2019054808A3 (fr) 2019-05-31

Family

ID=65723663

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/010873 WO2019054808A2 (fr) 2017-09-15 2018-09-14 Utilisation de peptides en tant qu'agent thérapeutique contre des maladies auto-immunes et des maladies osseuses

Country Status (1)

Country Link
WO (1) WO2019054808A2 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110143993A1 (en) * 2009-12-15 2011-06-16 The Brigham And Women's Hospital, Inc. Endothelial basement membrane targeting peptide ligands
WO2012153337A2 (fr) * 2011-05-11 2012-11-15 Technion Research & Development Foundation Ltd. Peptides antimicrobiens et leurs utilisations
WO2014007547A1 (fr) * 2012-07-03 2014-01-09 Il Yang Pharm. Co.,Ltd. Nouveaux peptides et leur utilisation
US9597274B2 (en) * 2015-06-17 2017-03-21 Avon Products, Inc. Peptides and their use in the treatment of skin
CN108431020B (zh) * 2016-03-09 2022-03-29 凯恩塞恩斯株式会社 用于预防或治疗炎症性疾病的肽及其应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NAT PROTOC., vol. 2, no. 5, 2007, pages 1269 - 75
See also references of EP3682892A4

Also Published As

Publication number Publication date
WO2019054808A3 (fr) 2019-05-31

Similar Documents

Publication Publication Date Title
JPH01305099A (ja) ペプチド誘導体
WO2019054808A2 (fr) Utilisation de peptides en tant qu'agent thérapeutique contre des maladies auto-immunes et des maladies osseuses
WO2019054809A2 (fr) Utilisation de peptides en tant qu'agent thérapeutique contre des maladies auto-immunes et des maladies osseuses
US20080311103A1 (en) Anti-Inflammatory Peptides and Methods of Use Thereof
WO2020171274A1 (fr) Peptide ayant une activité prophylactique ou thérapeutique contre une maladie inflammatoire ou auto-immune et utilisation associée
US20230234985A1 (en) Use of peptides as therapeutic agent for autoimmune diseases and bone diseases
KR20190031183A (ko) 자가면역질환 치료제로서의 펩타이드의 용도
US11730788B2 (en) Use of peptides as therapeutic agent for autoimmune diseases and bone diseases
KR20190031182A (ko) 골질환 치료제로서의 펩타이드의 용도
KR20190031185A (ko) 자가면역질환 치료제로서의 펩타이드의 용도
WO2021040416A1 (fr) Composition pharmaceutique pour prévenir ou traiter la perte osseuse induite par des maladies métaboliques osseuses, comprenant un extrait d'artemisia scoparia en tant que principe actif
KR20190031184A (ko) 골질환 치료제로서의 펩타이드의 용도
KR20190031070A (ko) 치료제로서의 펩타이드의 용도
KR102219926B1 (ko) 치료제로서의 펩타이드의 용도
KR20200084828A (ko) 치료제로서의 펩타이드의 용도
WO2024122720A1 (fr) Peptide pour régénérer le cartilage et ses utilisations
MX2011010190A (es) Metalopeptidos inmunomoduladores (immp) y composiciones que los contienen.
WO2024122721A1 (fr) Peptide pour régénérer le cartilage et ses utilisations
WO2024122718A1 (fr) Peptide pour régénérer le cartilage et ses utilisations
WO2023219460A1 (fr) Composition comprenant une souche de lactobacillus fermentum et un modulateur du métabolisme pour prévenir ou traiter des maladies métaboliques à l'aide d'une polythérapie
WO2024122717A1 (fr) Peptide pour régénérer le cartilage et ses utilisations
WO2024122716A1 (fr) Peptide pour régénérer le cartilage et ses utilisations
KR20230000792A (ko) 면역억제제 불응하는 자가면역질환의 치료제로서의 sd282의 용도

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18857312

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3075607

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2020515231

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018332486

Country of ref document: AU

Date of ref document: 20180914

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2018857312

Country of ref document: EP

Effective date: 20200415